DXCM vs. UTHR
DXCM (DexCom, Inc.) and UTHR (United Therapeutics Corporation) are both stocks. Both are in the Healthcare sector — DXCM in Diagnostics & Research, UTHR in Biotechnology. Over the past 10 years, DXCM returned 15.17%/yr vs 17.67%/yr for UTHR. At a 0.23 correlation, their price movements are largely independent.
Performance
DXCM vs. UTHR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DXCM achieves a 13.56% return, which is significantly higher than UTHR's 12.05% return. Over the past 10 years, DXCM has underperformed UTHR with an annualized return of 15.17%, while UTHR has yielded a comparatively higher 17.67% annualized return.
DXCM
- 1D
- 0.16%
- 1M
- 28.68%
- YTD
- 13.56%
- 6M
- 12.56%
- 1Y
- -9.03%
- 3Y*
- -15.73%
- 5Y*
- -5.51%
- 10Y*
- 15.17%
UTHR
- 1D
- 0.10%
- 1M
- -5.79%
- YTD
- 12.05%
- 6M
- 10.52%
- 1Y
- 90.80%
- 3Y*
- 33.49%
- 5Y*
- 24.97%
- 10Y*
- 17.67%
DXCM vs. UTHR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
DXCM DexCom, Inc. | 13.56% | -14.66% | -37.33% | 9.58% | -15.64% | 45.23% | 69.02% | 82.59% | 108.75% | -3.87% |
UTHR United Therapeutics Corporation | 12.05% | 38.09% | 60.46% | -20.93% | 28.70% | 42.35% | 72.33% | -19.12% | -26.39% | 3.15% |
Correlation
The correlation between DXCM and UTHR is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.05 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Apr 14, 2005 | 0.23 |
The correlation between DXCM and UTHR shifts across timeframes, from 0.05 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.
Fundamentals
DXCM:
$29.67B
UTHR:
$25.77B
DXCM:
$2.31
UTHR:
$27.00
DXCM:
32.57
UTHR:
20.22
DXCM:
0.77
UTHR:
0.66
DXCM:
6.29
UTHR:
8.21
DXCM:
10.03
UTHR:
4.37
DXCM:
$4.82B
UTHR:
$3.17B
DXCM:
$2.96B
UTHR:
$2.74B
DXCM:
$1.37B
UTHR:
$1.75B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DXCM vs. UTHR — Risk / Return Rank
DXCM
UTHR
DXCM vs. UTHR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DXCM | UTHR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.15 | ||
| Sortino ratioReturn per unit of downside risk | -4.27 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.49 | -0.49 |
| Calmar ratioReturn relative to maximum drawdown | -0.23 | 8.58 | -8.81 |
| Martin ratioReturn relative to average drawdown | -0.40 | 20.13 | -20.52 |
Loading charts...
Drawdowns
DXCM vs. UTHR - Drawdown Comparison
The maximum DXCM drawdown since its inception was -94.61%, roughly equal to the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for DXCM and UTHR.
Loading charts...
Drawdown Indicators
| DXCM | UTHR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.61% | -93.18% | -1.43% |
Max Drawdown (1Y)Largest decline over 1 year | -38.75% | -10.64% | -28.11% |
Max Drawdown (3Y)Largest decline over 3 years | -60.95% | -33.00% | -27.95% |
Max Drawdown (5Y)Largest decline over 5 years | -66.32% | -33.00% | -33.32% |
Max Drawdown (10Y)Largest decline over 10 years | -66.32% | -55.56% | -10.76% |
Current DrawdownCurrent decline from peak | -53.71% | -8.51% | -45.20% |
Average DrawdownAverage peak-to-trough decline | -36.02% | -35.31% | -0.71% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.77% | 4.53% | +18.24% |
Volatility
DXCM vs. UTHR - Volatility Comparison
DexCom, Inc. (DXCM) has a higher volatility of 13.27% compared to United Therapeutics Corporation (UTHR) at 5.01%. This indicates that DXCM's price experiences larger fluctuations and is considered to be riskier than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DXCM | UTHR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.27% | 5.01% | +8.26% |
Volatility (6M)Calculated over the trailing 6-month period | 25.48% | 25.94% | -0.46% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.74% | 47.55% | -6.81% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 46.98% | 35.08% | +11.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 48.43% | 35.06% | +13.37% |
Dividends
DXCM vs. UTHR - Dividend Comparison
Neither DXCM nor UTHR has paid dividends to shareholders.
Financials
DXCM vs. UTHR - Financials Comparison
This section allows you to compare key financial metrics between DexCom, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DXCM vs. UTHR - Profitability Comparison
DXCM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a gross profit of 750.30M and revenue of 1.19B. Therefore, the gross margin over that period was 63.0%.
UTHR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a gross profit of 648.10M and revenue of 781.50M. Therefore, the gross margin over that period was 82.9%.
DXCM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported an operating income of 255.30M and revenue of 1.19B, resulting in an operating margin of 21.4%.
UTHR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported an operating income of 325.80M and revenue of 781.50M, resulting in an operating margin of 41.7%.
DXCM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a net income of 199.50M and revenue of 1.19B, resulting in a net margin of 16.7%.
UTHR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a net income of 274.90M and revenue of 781.50M, resulting in a net margin of 35.2%.
Frequently Asked Questions
DXCM and UTHR have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DXCM has higher volatility (13.27%) compared to UTHR (5.01%). In terms of maximum drawdown, DXCM dropped -94.61% vs UTHR's -93.18%.
UTHR currently has the higher Sharpe Ratio (1.92 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DXCM and UTHR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer